Insights into advanced therapies in the context of evolving funding and M&A environments

Cell & Gene Therapy Insights 2024; 10(3), 223–229

DOI: 10.18609/cgti.2024.034

Published: 26 March
Lee Brown

David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.